GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » Change In Receivables

CLDI (Calidi Biotherapeutics) Change In Receivables : $0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Calidi Biotherapeutics Change In Receivables?

Calidi Biotherapeutics's change in receivables for the quarter that ended in Dec. 2024 was $0.00 Mil. It means Calidi Biotherapeutics's Accounts Receivable stayed the same from Sep. 2024 to Dec. 2024 .

Calidi Biotherapeutics's change in receivables for the fiscal year that ended in Dec. 2024 was $0.00 Mil. It means Calidi Biotherapeutics's Accounts Receivable stayed the same from Dec. 2023 to Dec. 2024 .

Calidi Biotherapeutics's Accounts Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Calidi Biotherapeutics's liquidation value for the three months ended in Dec. 2024 was $-2.62 Mil.

Calidi Biotherapeutics Change In Receivables Historical Data

The historical data trend for Calidi Biotherapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calidi Biotherapeutics Change In Receivables Chart

Calidi Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Change In Receivables
- - - - -

Calidi Biotherapeutics Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Calidi Biotherapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Calidi Biotherapeutics  (AMEX:CLDI) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Calidi Biotherapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of liquidation value, Calidi Biotherapeutics's accounts receivable are only considered to be worth 75% of book value:

Calidi Biotherapeutics's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=9.591-12.214+0.75 * 0+0.5 * 0
=-2.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Calidi Biotherapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Calidi Biotherapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Calidi Biotherapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » Change In Receivables
Comparable Companies
INAB AFMD ABVC PHGE BIVI EQ MBRX BOLT ZEOX SABS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
4475 Executive Drive, Suite 200, San Diego, CA, USA, 92121
Website
https://www.calidibio.com
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.